BCMA靶向治疗复发难治性AL淀粉样变性的疗效与安全性:描述性汇总分析
该研究对已发表研究进行系统描述性汇总分析,纳入256例接受BCMA靶向治疗(CAR-T、双特异性抗体、抗体偶联药物)的复发难治性AL淀粉样变性患者。汇总总体缓解率为83%,CAR-T为92%、双特异性抗体为89%、抗体偶联药物为68%;安全性总体可控,但抗体偶联药物眼部毒性突出。
要点
- BCMA靶向治疗在经重度治疗的AL淀粉样变性中汇总ORR达83%。
- CAR-T与双特异性抗体深度血液学缓解率约70%,ADC为64%。
- ADC眼部毒性发生率高(任何级别84%,≥3级29%)。
核心结论
- BCMA靶向治疗在经重度治疗的复发难治性AL淀粉样变性患者中产生高缓解率且安全性可控,支持继续研究和临床应用。
研究设计与样本
- 对已发表研究进行系统描述性汇总分析,纳入256例接受BCMA靶向治疗的患者。
- CAR-T治疗89例(35%),双特异性抗体82例(32%),抗体偶联药物85例(33%)。
主要发现
- 汇总总体缓解率为83%,CAR-T为92%,双特异性抗体为89%,抗体偶联药物为68%。
- 深度血液学缓解(≥非常好的部分缓解)在CAR-T和双特异性抗体受者中约70%,抗体偶联药物受者为64%。
- 可评估CAR-T患者中75%记录到微小残留病阴性,可评估双特异性抗体患者中为86%。
- 可评估患者中30%观察到器官缓解,其中心脏缓解为41%。
- 细胞因子释放综合征在CAR-T中发生74%、双特异性抗体中49%,主要为1-2级;≥3级罕见(CAR-T 9%,双特异性抗体1%)。
关键数值与推荐
- 抗体偶联药物受者眼部毒性为主要不良事件:任何级别84%,≥3级29%。
- ≥3级感染在CAR-T中为13%,双特异性抗体中为20%,抗体偶联药物中为6%。
临床怎么用
- BCMA靶向治疗可用于经重度治疗的复发难治性AL淀粉样变性,但需注意CAR-T和双特异性抗体的细胞因子释放综合征及ADC的眼部毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA)-targeted therapies have emerged as promising treatment options for patients with relapsed/refractory immunoglobulin light-chain (AL) amyloidosis. However, comprehensive data on their efficacy and safety remain limited. We conducted a systematic descriptive pooled analysis of published studies reporting outcomes of BCMA-directed therapies including chimeric antigen receptor T-cell (CAR-T) therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs). The analysis included 256 patients. CAR-T therapy was administered to 89 patients (35%), BsAbs to 82 patients (32%), and ADCs to 85 patients (33%). The pooled overall response rate (ORR) was 83%, with CAR-T demonstrating 92% ORR; BsAbs, 89%; and ADCs, 68%. Deep hematologic responses (≥very good partial response) were achieved in ∼70% of CAR-T and BsAb recipients and 64% of ADC recipients. Minimal residual disease negativity was documented in 75% of evaluable CAR-T patients and in 86% of evaluable BsAb patients with reported data. Organ responses were observed in 30% of evaluable patients, with cardiac responses in 41%. Cytokine release syndrome (CRS) occurred in 74% of CAR-T and 49% of BsAb patients, predominantly grade 1 to 2. Grade ≥3 CRS was rare (9% in CAR-T and 1% in BsAb). Ocular toxicity was the predominant adverse event in ADC recipients (84% with any grade and 29% with grade ≥3). Grade ≥3 infections occurred in 13% of CAR-T, 20% of BsAb, and 6% of ADC patients. BCMA-targeted therapies result in high response rates with manageable safety profiles among patients with heavily pretreated AL amyloidosis, supporting continued investigation and clinical application of these approaches.
引用
- Alqazaqi R, Taasan S, Schwartzman W, et al. Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis. Blood Adv. 2026. PMID: 42478693. doi:10.1182/bloodadvances.2026020740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。